EP4025214A1 — Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
Assigned to Arcutis Biotherapeutics Inc · Expires 2022-07-13 · 4y expired
What this patent protects
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflurmilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfac…
USPTO Abstract
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflurmilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
Drugs covered by this patent
- Daliresp (ROFLUMILAST) · Arcutis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.